ArticleCureus2025
Serum Vitamin D Level and Clinical Risk Factors for Benign Paroxysmal Positional Vertigo.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between serum 25-hydroxyvitamin D levels and prognosis in benign paroxysmal positional vertigo.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify the most prevalent comorbidities and the serum 25-hydroxyvitamin D levels that affect the onset and recurrence of benign paroxysmal positional vertigo. STUDY
designThis is a prospective cross-sectional descriptive study.
settingThe study was conducted at Hospital Universitario "Jose Eleuterio Gonzalez" in Monterrey, Mexico.
methodsA total of 117 patients over 18 years old who came for the first time to consultation complaining of dizziness and/or vertigo compatible with benign paroxysmal positional vertigo were included. Patients with positive vertiginous symptoms evoked with diagnostic test maneuvers were treated. A complete medical history was registered, the Dizziness Handicap Inventory was applied, and 25-hydroxyvitamin D serum levels were measured.
resultsFrom a total of 70 patients, the most prevalent comorbidities present were arterial hypertension (37.6%) and type 2 diabetes mellitus (29.1%). The most common cause of benign paroxysmal positional vertigo was idiopathic (67.5%), while in the secondary group, sudden neurosensorial hearing loss was the most common condition (6%). The mean average serum 25-hydroxyvitamin D level was 23.07 ng/ml, and insufficiency (42.9%) was the most common serum level present in the population of the study.
conclusionsThe comorbidities identified in this study, along with the deficiency levels of 25-hydroxyvitamin D, were factors associated with BPPV in our cohort and may have contributed to the onset and recurrence of benign paroxysmal positional vertigo; thus, we suggest that prospective studies should address this possible association and, if so, treat it to accomplish an effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.